# A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

> **NCT01125800** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Medulloblastoma
- Rhabdomyosarcoma
- Neuroblastoma
- Hepatoblastoma
- Glioma
- Astrocytoma

## Interventions

- **DRUG:** LDE225

## Key facts

- **NCT ID:** NCT01125800
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125800, "A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01125800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*